No Data
No Data
Investors Appear Satisfied With Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Prospects
Changzhou Qianhong Biopharma: Summary of Half-Year Report in 2024.
Changzhou Qianhong Biopharma: Half-year report for the year 2024.
Changzhou Qianhong Biopharma (002550.SZ): Net income in the first half of the year reached 0.183 billion yuan, a year-on-year increase of 53.57%.
On August 15, Gelunhui reported that Changzhou Qianhong Biopharma (002550.SZ) published its 2024 interim report, achieving revenue of 0.856 billion yuan and net income attributable to shareholders of listed companies of 0.183 billion yuan in the first half of the year, an increase of 53.57% compared to the same period last year. The net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 0.179 billion yuan, an increase of 60.64% compared to the same period last year, with basic earnings per share of 0.1457 yuan. The main reason is due to the company's active response to the severe and complex ecological environment of the domestic and foreign pharmaceutical industry, timely grasping industry global strategy opportunities, and implementing scientific and rational production, supply, and marketing.
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has A Pretty Healthy Balance Sheet
Changzhou Qianhong Biopharma: Changzhou Qianhong Biopharma: Performance Forecast for the First Half of 2024.
No Data
No Data